UNSPSC 51383301: Lumiracoxib

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13ClFNO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V91T9204HU, chemically known as benzeneacetic acid, 2-((2-chloro-6-fluorophenyl)amino)-5-methyl- but generally known as lumiracoxib, which bears US NIH Compound Identifier 151166. European Medicines Agency schedules Lumiracoxib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21406.

UNSPSC 51383301 Lumiracoxib, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The single recent opportunity on record—Seminole County, Florida's IFB for Naloxone and Safe Drug Deactivation Systems—concerns emergency response pharmaceuticals and harm-reduction equipment, not lumiracoxib (a nonsteroidal anti-inflammatory drug used for pain management). The mismatch between the code's nominal scope and the actual solicitation indicates minimal relevant recent activity under this Commodity code in state and local procurement.

Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract carries a two-year initial term with a one-year renewal option and includes E-Verify compliance, drug-free workplace certification, and standard insurance requirements. The procurement does not specify set-aside designations. Without additional recent opportunities tagged to this code, the code shows no clear activity in state and local procurement for lumiracoxib or related products.